Maximizing ventricular function with multimodal cell-based gene therapy.

Area of Science:

• Cardiovascular Research
• Regenerative Medicine
• Gene Therapy

Background:

• Vascular endothelial growth factor (VEGF) enhances angiogenesis in myocardial scars.
• Insulin-like growth factor I (IGF-I) may promote hypertrophy and inhibit apoptosis.
• Bone marrow cell (BMC) transplantation is a potential therapy for cardiac damage.

Purpose of the Study:

• To evaluate the efficacy of cell-based IGF-I and VEGF multigene therapy.
• To assess the impact on left ventricular (LV) function, cell survival, and apoptosis.
• To determine the benefits after BMC transplantation in a rat myocardial infarction model.

Main Methods:

• Lewis rats with induced myocardial infarction received BMCs engineered to express VEGF, IGF-I, or both.
• Gene expression, cell survival, apoptosis, and LV function were quantified over 4 weeks.
• Techniques included real-time PCR, TUNEL staining, echocardiography, and Western blotting.

Main Results:

• Co-expression of VEGF and IGF-I in BMCs significantly increased IGF-I and VEGF levels in the scar tissue.
• Transplanted cell survival was highest in the VEGF+IGF-I group.
• Apoptosis was reduced, and LV ejection fraction was significantly improved in the combined gene therapy group compared to controls and single-gene therapy groups.

Conclusions:

• Transplantation of BMCs expressing both VEGF and IGF-I effectively reduces apoptosis and enhances transplanted cell survival.
• This multimodal, cell-based gene therapy approach maximizes left ventricular function recovery post-myocardial infarction.
• Combined gene therapy holds promise for improving outcomes in cell transplantation strategies for heart disease.